Papadimitrakopoulou V, et al. IMPOWER132: PFS and safety results with 1L atezolimumab + carboplatin/cisplatin + pemetrexed in stage IV non-squamous NSCLC. IASLC 2018; abstract OA05.07.
Lutetium-177 PSMA-617 zet belangrijke stap richting kliniek
nov 2018 | Uro-oncologie